Schizophrenia Studies Should Open Dialog
Posted on: Friday, 1 December 2006, 12:01 CST
Recent studies on schizophrenia treatment and cost should spark discovery of a third generation of treatment, a U.S. mental health advocacy group said.
A series of studies on the treatment of schizophrenia confirmed what many thought -- first generation drugs cost less than second-generation advancements and, as a class, second-generation drugs were no more effective than first, said Ken Duckworth, medical director of the National Alliance on Mental Illness.
The studies also warned against treatment based on cost, not the individual patient's needs, Duckworth said.
Broad findings remain subject to the fact that 'one size does not fit all' in choosing the right medication for a patient, Duckworth said, which the National Institute of Mental Health, which funded the studies, also emphasized.
Because second-generation drugs changed the side effects but not the drugs' effectiveness, Duckworth said, "The time has come for a third generation of medications for schizophrenia.
Duckworth said the most important contribution of the studies lies in stimulating new ways of thinking about medication treatment for schizophrenia, and providing a base for the next generation.
Source: United Press International
Related Articles
- Study: Split Drug Prices, Marketing Costs
- Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
- Study: Medicare Drug Plan Cutting Costs for Seniors
- New Approaches to Drug Development Will Drive Drug Company Success, According to Tufts Center for the Study of Drug Development
- Despite Development Challenges, Drug Developers Have Reason to Be Optimistic, According to Tufts Center for the Study of Drug Development
- Clinical Study of Drug-Free Psoriasis Treatment Under Way
- ValueOptions and Colorado Health Networks Win Administrative Services Only Contract; Social Security Administration's Mental Health Treatment Study Contract Awarded to Westat With ValueOptions and Colorado Health Networks Serving As ASO
- After Years of Declining R&D Productivity, Drug Development Is Poised to Take Off, According to Tufts Center for the Study of Drug Development
- Drugs equivalent in angina treatment: study
- University Studies Show Little Progress in New Mental Health Medication
 |
 |
User Comments (0)
RSS Feeds